Case Pits Generic Drug Makers Against Insurers, Stores
prices for consumers would be even lower if those companies did not strike deals to restrain trade. Drugstore chains and health insurers back the governments side.
March 06--Generic drugs have dramatically changed the pharmaceutical and health-care landscape in the last 25 years and now account for about 80 percent of prescriptions in the United States, with lower prices for consumers and insurers.
But a U.S. Supreme Court case scheduled for argument March 25 pits drug companies, generic and branded, against government officials who argue that prices for consumers would be even lower if those companies did not strike deals to restrain trade. Drugstore chains and health insurers back the government’s side.
Trying to buttress his case, Ralph Neas, president of the Generic Pharmaceutical Association, said in a conference call with reporters Tuesday that the ruling "will define how an entire industry does business." An adverse decision will hurt drug makers, consumers, and taxpayers, who pay the drug bill through public or private insurance, he argued.
Teva Pharmaceutical Industries Ltd., whose American headquarters is in North Wales, was among the pioneers of a practice leading to the debate. Teva joined other generic drug makers in filing a brief in support of the four companies sued by the Federal Trade Commission. Local brand-name companies Merck and Shire also filed briefs in support.
"The facts, public policy, and the law don’t support the FTC," Neas said.
In its suit, the FTC says generic and brand-name drug makers enter "reverse payment" or "pay-to-delay" deals violating the Sherman Antitrust Act.
Such arrangements typically work like this: A brand-name company pays for research to gain Food and Drug Administration approval to sell a patented drug, for which the company gets market exclusivity until the patent expires, often 12 or more years. Such exclusivity allows the manufacturer to charge high prices, recoup costs, and make profits. A generic company then files an FDA application, claiming its version is close in safety and efficacy but does not copy the original. Then the brand-name firm sues for patent infringement.
Sometimes, the suit goes to trial. But often, the sides negotiate a settlement that allows the generic company to sell its drug earlier than if it waited until the patent expired, but not as early as it wanted. The brand-name company often pays the generic company, figuring the certainty of costs and revenue is better than the uncertain chance for greater profit.
According to the FTC, in fiscal 2012 there were 40 such deals, 12 more than the year before, involving 31 products whose sales were more than $8.3 billion.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance